Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Italian Start-up CellPly Snares $2.8M Seed Investment

Italian Start-up CellPly Snares $2.8M Seed Investment

Mar 21, 2014
|
staff reporter

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Italian Angels for Growth, Zernike Meta Ventures, and Atlas Seed made the investment into Bologna, Italy-based CellPly in order to support the firm's completion of its diagnostics platform, which is being developed to allow clinicians to assess in vitro a patient's cellular response to cancer treatments, such as chemotherapy and monoclonal antibodies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

What's Popular?

In Cancer

  1. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  2. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  3. Deepcell Advancing AI-Driven Cell Morphology Tech for Single-Cell Genomics, Liquid Biopsy

    Premium

  4. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  5. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.